Search research articles
Contact Us
Filters
Showing results (301-310 of 318) with videos related to
Page
of 32
Sort By:
Malaria Journal
|
September 23, 2015
Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis
, Salim Abdulla, Elizabeth A Ashley, et al.
Science Translational Medicine
|
July 22, 2021
The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to <i>Plasmodium falciparum</i> parasite resistance
James M Murithi, Cécile Pascal, Jade Bath, et al.
Plos Medicine
|
November 19, 2020
The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network
Mohammad S Hossain, Robert J Commons, Nicholas M Douglas, et al.
Malaria Journal
|
November 14, 2025
Automated reporting of primaquine dose efficacy, tolerability and safety for Plasmodium vivax malaria using a systematic review and individual patient data meta-analysis
Peta Edler, Megha Rajasekhar, David J Price, et al.
Nature Communications
|
May 25, 2017
A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance
Paul M O'Neill, Richard K Amewu, Susan A Charman, et al.
BMC Medicine
|
August 2, 2019
The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis
Robert J Commons, Julie A Simpson, Kamala Thriemer, et al.
The Lancet. Infectious Diseases
|
July 24, 2018
The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis
Robert J Commons, Julie A Simpson, Kamala Thriemer, et al.
The American Journal of Tropical Medicine and Hygiene
|
July 23, 2014
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine
Meera Venkatesan, Nahla B Gadalla, Kasia Stepniewska, et al.
The Lancet. Infectious Diseases
|
February 14, 2026
Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial
Tamiru Shibiru Degaga, Ayodhia Pitaloka Pasaribu, Rupam Tripura, et al.
Malaria Journal
|
April 7, 2017
Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group
Kamala Thriemer, Benedikt Ley, Albino Bobogare, et al.
Page
of 32
Search research articles
Search
Showing results (301-310 of 318) with videos related to
Sort By:
Page
of 32
Malaria Journal
|
September 23, 2015
Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis
, Salim Abdulla, Elizabeth A Ashley, et al.
Science Translational Medicine
|
July 22, 2021
The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to <i>Plasmodium falciparum</i> parasite resistance
James M Murithi, Cécile Pascal, Jade Bath, et al.
Plos Medicine
|
November 19, 2020
The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network
Mohammad S Hossain, Robert J Commons, Nicholas M Douglas, et al.
Malaria Journal
|
November 14, 2025
Automated reporting of primaquine dose efficacy, tolerability and safety for Plasmodium vivax malaria using a systematic review and individual patient data meta-analysis
Peta Edler, Megha Rajasekhar, David J Price, et al.
Nature Communications
|
May 25, 2017
A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance
Paul M O'Neill, Richard K Amewu, Susan A Charman, et al.
BMC Medicine
|
August 2, 2019
The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis
Robert J Commons, Julie A Simpson, Kamala Thriemer, et al.
The Lancet. Infectious Diseases
|
July 24, 2018
The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis
Robert J Commons, Julie A Simpson, Kamala Thriemer, et al.
The American Journal of Tropical Medicine and Hygiene
|
July 23, 2014
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine
Meera Venkatesan, Nahla B Gadalla, Kasia Stepniewska, et al.
The Lancet. Infectious Diseases
|
February 14, 2026
Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial
Tamiru Shibiru Degaga, Ayodhia Pitaloka Pasaribu, Rupam Tripura, et al.
Malaria Journal
|
April 7, 2017
Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group
Kamala Thriemer, Benedikt Ley, Albino Bobogare, et al.
Page
of 32